Clinical Trials Directory

Trials / Completed

CompletedNCT03642210

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
105 (actual)
Sponsor
Medicines360 · Academic / Other
Sex
Female
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

To assess the efficacy of a levonorgestrel 52 mg intrauterine system as a treatment for heavy menstrual bleeding.

Detailed description

This study is a multicenter, open-label, evaluation of the efficacy and safety of LNG20 IUS for treatment of heavy menstrual bleeding.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTLevonorgestrel 52 mg intrauterine systemLevonorgestrel 52 mg intrauterine system

Timeline

Start date
2019-01-17
Primary completion
2021-10-12
Completion
2021-10-12
First posted
2018-08-22
Last updated
2024-05-14
Results posted
2024-05-14

Locations

29 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03642210. Inclusion in this directory is not an endorsement.

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding (NCT03642210) · Clinical Trials Directory